Citadel Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Citadel Advisors’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,700	Closed	-$30.5K	–	15790
2024 Q3	$30.5K	Buy	+40,700	New	+$36.2K	﹤0.01%	12421
2023 Q2	–	Sell	-1,580	Closed	-$9.24K	–	15477
2023 Q1	$9.24K	Buy	+1,580	New	+$9.25K	﹤0.01%	13596
2022 Q2	–	Sell	-5,720	Closed	-$56K	–	14433
2022 Q1	$56K	Sell	5,720 -240	-4%	-$2.33K	﹤0.01%	12723
2021 Q4	$56K	Buy	5,960 +260	+5%	+$3.33K	﹤0.01%	13188
2021 Q3	$88K	Sell	5,700 -880	-13%	-$15.1K	﹤0.01%	12995
2021 Q2	$140K	Buy	6,580 +360	+6%	+$7.26K	﹤0.01%	12571
2021 Q1	$130K	Sell	6,220 -5,800	-48%	-$133K	﹤0.01%	12205
2020 Q4	$216K	Buy	12,020 +3,720	+45%	+$61.5K	﹤0.01%	9623
2020 Q3	$144K	Buy	+8,300	New	+$155K	﹤0.01%	9028

Other funds holding GENE

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's GENE Position: Q4 2024 in Review

Citadel Advisors sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 682 shares — an estimated $510 sold.

Citadel Advisors first reported a position in GENE in Q1 2014 and held it in 24 quarters. The position peaked at $438K in Q1 2021. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.

Citadel Advisors reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 682 Genetic Technologies Ltd. shares in Q4 2024, an estimated $510.
Citadel Advisors first reported a position in Genetic Technologies Ltd. in Q1 2014 and held it in 24 quarters.
Citadel Advisors's Genetic Technologies Ltd. position peaked at $438K in Q1 2021.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.